Larimar Therapeutics announce plans for phase 3 trial of Nomlabofusp for FA - Ataxia UK

Larimar Therapeutics announce plans for phase 3 trial of Nomlabofusp for FA

Post Published: April 3, 2025

On March 24th 2025, the pharmaceutical company Larimar Therapeutics announced their plans to start conducting a phase 3 trial of their Friedreich’s ataxia (FA) drug Nomlabofusp in mid-2025. 

This follows positive results in their phase 2 trial, which you can read about here.

Data from those taking the 50mg dose of Nomlabofusp in the open-label extension study and the adolescent cohort are expected by September 2025. Larimar plan to submit an application to the FDA for an accelerated approval of Nomlabofusp by the end of 2025.

Read more in their press release here.

RECENT POSTS

MHRA approves Omaveloxolone for Friedreich’s ataxia

Read More →

Living with Late Onset – Clare’s Friedreich’s ataxia Story

Read More →

New study published on goal-directed Rehabilitation vs. Standard Care in those with hereditary Cerebellar ataxia

Read More →

Subscribe To Our Newsletter

fundraise image

FUNDRAISE FOR US

Take part in a challenge or create your fundraiser. Every penny you raise will help those affected by ataxia.

Click to find out more
Donate Image

DONATE

To make either a one off or recurring donation which will help fund research into treatments and cures and supports those affected ataxia

Click Here
Volunteer Image

VOLUNTEER WITH US

Support the ataxia community and volunteer with Ataxia UK. From social media to telephone befriending, there are loads of ways you can make a difference to someone's life.

Click to find out more
Cart
Checkout - £0.00
  • 0
  • 1
Scroll to Top